EI
IMMX icon

EAM Investors’s Immix Biopharma IMMX Stock Holding History

EAM Investors’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$957K Sell
92,825
-28,031
-23% -$260K 0.09% 228
2026
Q1 		$1.1M Hold
120,856
– – 0.13% 205
2025
Q4 		$632K Buy
+120,856
New +$497K 0.07% 247
2024
Q1 		– Sell
-102,661
Closed -$710K – 287
2023
Q4 		$710K Buy
+102,661
New +$465K 0.13% 194

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EAM Investors's IMMX Position: Q2 2026 in Review

EAM Investors reduced its Immix Biopharma (IMMX) stake by 23% in Q2 2026, selling an estimated $260K and leaving 92,825 shares worth $957K. The position accounts for 0.09% of the portfolio, ranked #228.

EAM Investors first reported a position in IMMX in Q4 2023 and has held it in 4 quarters since. The position peaked at $1.1M in Q1 2026. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • EAM Investors held 92,825 shares of Immix Biopharma worth $957K as of Q2 2026.
  • EAM Investors sold 28,031 Immix Biopharma shares in Q2 2026, an estimated $260K.
  • Immix Biopharma made up 0.09% of EAM Investors's portfolio in Q2 2026, its #228 holding.
  • EAM Investors first reported a position in Immix Biopharma in Q4 2023 and has held it in 4 quarters since.
  • EAM Investors's Immix Biopharma position peaked at $1.1M in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.